News

NeuroTrauma Sciences Enters Collaboration to Support “CENTER-TBI” Research in Traumatic Brain Injury

NeuroTrauma Sciences, LLC (NTS) today announced it has entered into a research collaboration with Antwerp University Hospital, Belgium, to help support “Collaborative European NeuroTrauma Effectiveness Research in TBI” (CENTER-TBI), a prospective longitudinal observational study that is collecting clinical and epidemiological data to identify the most effective clinical care and...

May 11, 2021

NeuroTrauma Sciences Announces Expansion of Its Executive Leadership Team

NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of acquired brain injury, today announced the expansion of its executive management team with several key appointments...

March 24, 2021

NeuroTrauma Sciences Enters Into Worldwide License Agreement with Emory University for Molecules to Treat Stroke and Traumatic Brain Injury

NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company, and Emory University (Emory), a non-profit organization, today announced that they have entered into a license agreement for patents and technology invented at Emory.

December 11, 2019

NeuroTrauma Sciences and Henry Ford Health System Announce Research and License Agreements to Develop Exosome Technology for Neurological Injury

Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury...

July 16, 2018

NeuroTrauma Sciences Enters Collaboration to Support “CENTER-TBI” Research in Traumatic Brain Injury

NeuroTrauma Sciences Announces Expansion of Its Executive Leadership Team

NeuroTrauma Sciences Enters Into Worldwide License Agreement with Emory University for Molecules to Treat Stroke and Traumatic Brain Injury

NeuroTrauma Sciences and Henry Ford Health System Announce Research and License Agreements to Develop Exosome Technology for Neurological Injury

Connect